Daiwa Securities Group’s Keros Therapeutics KROS Stock Holding History

Daiwa Securities Group’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-133	Closed	-$3K	–	1322
2025 Q4	$3K	Hold	133	–	–	﹤0.01%	1277
2025 Q3	$2K	Hold	133	–	–	﹤0.01%	1274
2025 Q2	$2K	Hold	133	–	–	﹤0.01%	1216
2025 Q1	$1K	Hold	133	–	–	﹤0.01%	1231
2024 Q4	$2K	Hold	133	–	–	﹤0.01%	1218
2024 Q3	$8K	Hold	133	–	–	﹤0.01%	1144
2024 Q2	$6K	Hold	133	–	–	﹤0.01%	1189
2024 Q1	$9K	Buy	133 +22	+20%	+$1.3K	﹤0.01%	1174
2023 Q4	$4K	Hold	111	–	–	﹤0.01%	1225
2023 Q3	$4K	Hold	111	–	–	﹤0.01%	1174
2023 Q2	$4K	Hold	111	–	–	﹤0.01%	1198
2023 Q1	$5K	Hold	111	–	–	﹤0.01%	1153
2022 Q4	$5K	Buy	111 +31	+39%	+$1.45K	﹤0.01%	1156
2022 Q3	$3K	Hold	80	–	–	﹤0.01%	1196
2022 Q2	$2K	Hold	80	–	–	﹤0.01%	1244
2022 Q1	$4K	Hold	80	–	–	﹤0.01%	1195
2021 Q4	$5K	Hold	80	–	–	﹤0.01%	1197
2021 Q3	$3K	Buy	80 +36	+82%	+$1.28K	﹤0.01%	1216
2021 Q2	$2K	Hold	44	–	–	﹤0.01%	1142
2021 Q1	$3K	Hold	44	–	–	﹤0.01%	1109
2020 Q4	$3K	Buy	+44	New	+$2.77K	﹤0.01%	1087

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Daiwa Securities Group's KROS Position: Q1 2026 in Review

Daiwa Securities Group sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 133 shares — an estimated $3K sold.

Daiwa Securities Group first reported a position in KROS in Q4 2020 and held it in 21 quarters. The position peaked at $9K in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Daiwa Securities Group reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
Daiwa Securities Group sold 133 Keros Therapeutics shares in Q1 2026, an estimated $3K.
Daiwa Securities Group first reported a position in Keros Therapeutics in Q4 2020 and held it in 21 quarters.
Daiwa Securities Group's Keros Therapeutics position peaked at $9K in Q1 2024.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.